$MRK (Merck & Co. Inc.)

$MRK {{ '2016-02-16T14:03:48+0000' | timeago}} • Announcement

Global healthcare company $MRK said that the U.S. FDA has issued a Complete Response Letter regarding its Supplemental New Drug Applications for ZETIA and VYTORIN for the reduction of the risk of cardiovascular events in patients with coronary heart disease. The applications were based on the results of IMPROVE-IT.

$MRK {{ '2017-07-26T13:49:00+0000' | timeago}} • Announcement

$MRK's BoD declared a quarterly dividend of $0.47 per share of its common stock for 4Q17. The dividend will be paid on Oct. 6, 2017 to shareholders of record at the close of business on Sept. 15, 2017.

$MRK {{ '2017-07-25T17:08:10+0000' | timeago}} • Announcement

$MRK announced the presentation of results from the Drive-Ahead study, the second of two pivotal Phase 3 clinical trials evaluating the efficacy and safety of doravirine, the company's investigational, non-nucleoside reverse transcriptase inhibitor (NNRTI), for the treatment of HIV-1 infection.

$MRK {{ '2017-07-25T11:50:57+0000' | timeago}} • Announcement

$MRK said that its anti-programmed cell death protein 1 (PD1) drug Keytruda (pembrolizumab) failed to meet the primary endpoint in the Phase III KEYNOTE-040 trial for previously treated recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). When compared with standard treatment, Keytruda failed to improve the overall survival rate.

$MRK {{ '2017-07-24T18:28:47+0000' | timeago}} • Announcement

$MRK today announced the US launch of RENFLEXIS, a biosimilar for Remicade, which was approved by FDA for all eligible indications. RENFLEXIS will have a wholesale acquisition cost of $753.39, which is a 35% discount compared to Remicade. Remicade was the fifth bestselling drug in the US in 2016 raking in $5.3Bil on an invoice price basis.

$MRK {{ '2017-07-21T15:21:07+0000' | timeago}} • Announcement

President Donald Trump announced that pharma giants $MRK and $PFE are collaborating with Gorilla Glass manufacturer Corning ($GLW) for manufacturing a new glass (Valor Glass), which is superior and reliable for the delivery of injectable drugs. Corning is planning to initially invest $500MM creating 1,000 jobs at 3 facilities in US.

$MRK {{ '2017-07-20T14:29:27+0000' | timeago}} • Announcement

$MRK announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval for its 100 units/mL insulin glargine injection, a follow-on biologic basal insulin in a pre-filled dosing device.

$MRK {{ '2017-07-06T12:50:08+0000' | timeago}} • Announcement

Pharma company $MRK will present its HIV portfolio and pipeline at the 9th IAS Conference on HIV Science. The presentations include late-breaker abstracts from two phase-3 pivotal clinical trials and a phase-1 study of MK-8591, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor in adult patients with HIV-1 infection.

$MRK {{ '2017-07-05T22:11:39+0000' | timeago}} • Announcement

$MRK said the US FDA has placed a clinical hold on KEYNOTE-183, KEYNOTE-185 and KEYNOTE-023, three combination studies of KEYTRUDA (pembrolizumab), the company’s anti-PD-1 therapy, in the blood cancer multiple myeloma. The FDA has determined that the risks of KEYTRUDA outweigh any potential benefit for patients with multiple myeloma.

$MRK {{ '2017-06-27T14:06:02+0000' | timeago}} • Announcement

$MRK provided update on Reveal outcomes study of anacetrapid. $MRK plans to review the results of the trial with external experts, and will consider whether to file new drug applications with the FDA and other regulatory agencies. The results will be presented at the European Society of Cardiology meeting on Aug. 29, 2017.

$MRK {{ '2017-06-27T14:04:38+0000' | timeago}} • Announcement

$MRK announced that the Reveal (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of anacetrapib met its primary endpoint, significantly reducing major coronary events compared to placebo in patients at risk for cardiac events who are already receiving an effective LDL-C lowering regimen.

$MRK {{ '2017-06-12T11:25:01+0000' | timeago}} • Announcement

$MRK, in partnership with $PFE, announced that two Phase 3 studies of ertugliflozin, an investigational oral drug to help improve glucose level control in adults with type 2 diabetes, met their primary endpoints.

$MRK {{ '2017-05-23T17:54:08+0000' | timeago}} • Announcement

$MRK's BoD declared a quarterly dividend of $0.47 per share of its common stock for 3Q17. The dividend will be payable on July 10, 2017 to shareholders of record at the close of business on June 15, 2017.

$MRK {{ '2017-05-02T13:03:59+0000' | timeago}} • Webcast

$MRK said that for HCV, it is seeing good progress with ZEPATIER, which is not only seen in the US but also in Europe & Japan. Looking at the HCV market, the market is large and has good opportunities, but would be played out over many years. However, $MRK is seeing a reduction in patients being treated in 2017 vs. 2016, which is going to continue.

$MRK {{ '2017-05-02T12:52:09+0000' | timeago}} • Webcast

$MRK stated that on the GM outlook for the rest of the year, the company continues to expect a moderate increase over 2016. In 1Q17, $MRK had a strong GM, driven largely by CapEx and discards.

$MRK {{ '2017-05-02T12:12:07+0000' | timeago}} • Infographic

$MRK Merck & Co. Inc. Earnings AlphaGraphics: Q1 2017 highlights

$MRK {{ '2017-05-02T11:17:22+0000' | timeago}} • Announcement

In 1Q17, $MRK's pharmaceutical sales rose 1% to $8.2Bil, driven by oncology, hepatitis C and vaccines. Growth in oncology was due to higher sales of KEYTRUDA. Animal Health sales totaled $939MM, an increase of 13% YoY. The growth was primarily due to sales increases in companion animal products, driven by BRAVECTO line of products.

$MRK {{ '2017-05-02T11:12:00+0000' | timeago}} • Announcement

$MRK narrowed and raised its FY17 GAAP EPS range to be between $2.51 and $2.63. FY17 non-GAAP EPS range was narrowed and raised to the range of $3.76-3.88. Meanwhile, it narrowed and raised its revenue range for the period to be between $39.1Bil and $40.3Bil.

$MRK {{ '2017-05-02T11:08:00+0000' | timeago}} • Announcement

Pharmaceutical giant $MRK posted worldwide sales of $9.4Bil in 1Q17, up 1%, driven by the continued momentum of KEYTRUDA in the treatment of tumors, as well as strength of other franchises and animal health. Net income was $1.55Bil, or $0.56 per share, up from $1.13Bil, or $0.40 per share in 1Q16. Adjusted for special items, EPS stood at $0.88.

$MRK {{ '2017-04-24T15:14:04+0000' | timeago}} • Announcement

$MRK announced new phase 2 data on investigational triple combination therapy MK-3682B for chronic hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatment with approved direct-acting antiviral regimens had failed.

$MRK {{ '2017-04-11T12:38:37+0000' | timeago}} • Announcement

$MRK announced that Dr John Noseworthy, CEO of Mayo Clinic, has been nominated to stand for election to it BoD. The election of Dr Noseworthy will take place at Merck’s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr Noseworthy and the planned retirement of Robert Kidder, the Merck board will have 13 members.

Recent Transcripts

BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, July 27 2017 - 2:00pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
PG (The Procter & Gamble Company)
Thursday, July 27 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
CCXI (ChemoCentryx, Inc.)
Wednesday, May 10 2017 - 9:00pm
ACAD (ACADIA Pharmaceuticals Inc.)
Tuesday, May 9 2017 - 9:00pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, May 9 2017 - 3:30pm
ATRS (Antares Pharma Inc.)
Tuesday, May 9 2017 - 12:30pm
ENDP (Endo International plc)
Tuesday, May 9 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, May 9 2017 - 12:00pm
ARQL (ArQule Inc.)
Wednesday, May 3 2017 - 1:00pm
AMRN (Amarin Corporation plc)
Wednesday, May 3 2017 - 12:00pm
GILD (Gilead Sciences Inc.)
Tuesday, May 2 2017 - 8:30pm
MRK (Merck & Co. Inc.)
Tuesday, May 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Monday, May 1 2017 - 9:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, April 27 2017 - 2:30pm
ALXN (Alexion Pharmaceuticals, Inc.)
Thursday, April 27 2017 - 2:00pm

AlphaGraphics you may like